ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: L04 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease

    Maaman Bashir1, Katherine Sherman 2, Sara K. Tedeschi 3 and Ann Rosenthal 1, 1Medical College of Wisconsin, Milwaukee, 2Milwaukee VAMC, Milwaukee, 3Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
  • Abstract Number: 182 • 2019 ACR/ARP Annual Meeting

    Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts

    Fenglong Xie 1, Cynthia Crowson 2, Iris Navarro-Millan 3, Monika Safford 3 and Jeffrey Curtis4, 1University of Alabama at Birmingham, Birmingham, 2Mayo Clinic Rochester, Rochester, 3Weill Cornell Medicine, New York, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Cardiovascular (CV) risk estimation across diverse rheumatoid arthritis (RA) cohorts may be challenging given potential heterogeneity in comorbidities and widely varying prevalence of CV…
  • Abstract Number: 1078 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study

    Dionicio Angel Galarza-Delgado 1, Iris Colunga-Pedraza 2, Jose Azpiri-Lopez 2, Karla Paola Cuellar-Calderon2, Ileana Cecilia Reynosa-Silva 2, Marielva Castro-Gonzalez 2 and Carolina Marlene Martinez-Flores 2, 1Universidad Autonoma de Nuevo Leon "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, 2Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Cardiovascular diseases are among the most common comorbidities in patients with rheumatic diseases (RD) and leads them to an overall increase of mortality in…
  • Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting

    The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

    Sicong Huang 1, Zeling He 1, Daniel Solomon 2, Elena Massarotti 3, Charlotte Golnik 1, Thany Seyok 1, Seth Brownmiller 4, Tianrun Cai 3, Nicole Yang 3, Laurel Campbell 3, Leanne Barrett 3, Courtney Bibbo 3, Kenneth Pariser 3, Derrick Todd 3, Marcy Bolster 4, Marcelo Di Carli 3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 3Brigham and Women's Hospital, Boston, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA).  We hypothesize that increased systemic inflammation leads to…
  • Abstract Number: 196 • 2019 ACR/ARP Annual Meeting

    Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Sofia Pedro 2, Rebecca Schumacher 2, Teresa Simon 3 and Kaleb Michaud 1, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Bristol-Myers Squibb*, Princeton, NJ

    Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…
  • Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting

    The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis

    Linh Truong1, Nicole Ridolfi 2, Eugenia Chen 2 and Maida wong 3, 1University of California, Irvine, San Diego, CA, 2University of California, Irvine, Orange, 3Tibor Rubin Veterans Affairs Medical Center, Long Beach

    Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
  • Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting

    Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity

    Annelies Blanken1, Rabia Agca 2, Conny van der Laken 3 and Mike Nurmohamed 4, 1Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, 3Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, 4Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
  • Abstract Number: 261 • 2019 ACR/ARP Annual Meeting

    Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample

    Shraddha Jatwani1, Karan Chugh 1, Bikramjit Bindra 2 and Karan Jatwani 3, 1St. Vincent Evansville, Evansville, 2Government Medical College & Hospital, Chandigarh, India, 3Mount Sinai West - St Luke’s Hospital, New York

    Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
  • Abstract Number: 1107 • 2019 ACR/ARP Annual Meeting

    Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?

    Dionicio Galarza-Delgado 1, Jose Azpiri-Lopez 1, Iris Colunga-Pedraza 1, Iván de Jesús Hernández-Galarza 1, Ileana Cecilia Reynosa-Silva1, Karla Paola Cuellar-Calderon 1, Marielva Castro-Gonzalez 1 and Carolina Marlene Martinez-Flores 1, 1Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Chronic systemic inflammation generated by rheumatic diseases (RD) is related to the increased cardiovascular risk (CVR) in this population. However, the coexistence of traditional…
  • Abstract Number: 2332 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients

    Hafis Muhammed1, Durga P Misra 1, Sujata Ganguly 1, Sarit Sekhar Pattanaik 1, Saurabh Chaturvedi 1, Harshit Singh 1, Mohit K Rai 1, Anamika Anuja 1, Namita Mohindra 1, Neeraj Jain 1, Sudeep Kumar 1 and Vikas Agarwal 1, 1SGPGI, Lucknow, Uttar Pradesh, India

    Background/Purpose: Rheumatoid arthritis(RA) patients have increased cardiovascular(CV) risk with no data on CV risk scores in Indian patients.The primary objective was to study prevalence of…
  • Abstract Number: 279 • 2019 ACR/ARP Annual Meeting

    Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases

    Keith Colaco1, Elsie Nguyen 2, Shadi Akhtari 3, Paula Harvey 3 and Lihi Eder 4, 1University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Women's College Hospital, Toronto, ON, Canada, 4Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada

    Background/Purpose: The value of non-invasive vascular imaging for cardiovascular (CV) risk stratification of patients with inflammatory rheumatic diseases is unclear. Measures of atherosclerosis including coronary…
  • Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting

    A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout

    Daisy Vedder 1, Martijn Gerritsen 1, Mike Nurmohamed 2, Ronald van Vollenhoven 3 and Christian Lood4, 1Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, 3Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, 4University of Washington, Seattle, WA

    Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…
  • Abstract Number: 2334 • 2019 ACR/ARP Annual Meeting

    Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?

    Brian Løgstrup1, Torkell Ellingsen 2, Alma Pedersen 3, Bianka Darvalics 3, Kevin Olesen 4, Hans Erik Bøtker 4 and Michael Mæng 4, 1Department of Cardiology, Aarhus University Hospital, Denmark, Aarhus, Syddanmark, Denmark, 2Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 4Department of Cardiology, Aarhus University Hospital, Denmark, Aarhus, Denmark

    Background/Purpose: To compare the risk of cardiovascular disease (CVD) and mortality in patients with rheumatoid arthritis (RA), diabetes mellitus (DM), and the general population.Methods: Patients…
  • Abstract Number: 316 • 2019 ACR/ARP Annual Meeting

    Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA

    Liliya Gandrabur1, Woo Young Kim 1, Aditi Sen 1, Deana Nes 1, Julia Ash 1, Amy Wasserman 1 and Kirk Sperber 1, 1Westchester Medical Center, Valhalla, NY

    Background/Purpose: Evidence suggests that the tools used for cardiovascular disease (CVD) risk assessment in the general population underestimate the true risk when they are applied…
  • Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting

    Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

    Eric Toussirot1, Hubert Marotte 2, denis Mulleman 3, gregoire Cormier 4, fabienne Coury-Lucas 5, Philippe Gaudin 6, Emmanuelle Dernis 7, christine bonnet 8, richard damade 9, jean-luc Grauer 10, Tassadit Ait Abdesselam 11, caroline Karras 12, frederic Liote 13, Pascal Hilliquin 14, antoinette sacchi 15, Jean-Marie Berthelot 16, marc puyraveau 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2University Hospital, St Etienne, France, 3University hospital, Tours, France, 4CHD Vendée, La Roche sur Yon, France, 5University Hospital, Lyon, France, 6Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 7Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 8University Hospital, Limoges, France, 9Centre Hospitalier, Chartres, France, 10Centre Hopsitalier, Montelimar, France, 11Centre Hospitalier, Meaux, France, 12Hôpital Saint Joseph, Marseille, France, 13AP-HP, Paris, France, 14Centre Hospitalier, Corbeil Essones, France, 15Centre Hospitalier, Mantes la Jolie, France, 16University Hospital, Nantes, France

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology